SYS-CON MEDIA Authors: Peter Silva, Kevin Jackson, Jessica Qiu, Dana Gardner, Dan Stolts

News Feed Item

Cancer Monoclonal Antibody Partnering Terms and Agreements



 

 

 

LONDON, Aug. 27, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Cancer Monoclonal Antibody Partnering Terms and Agreements

https://www.reportbuyer.com/product/1112622/Cancer-Monoclonal-Antibody-Partnering-Terms-and-Agreements.html

The Cancer Monoclonal Antibody Partnering Agreements report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies.


Trends in cancer monoclonal antibody partnering deals
Disclosed headlines, upfronts, milestones and royalties by stage of development
Cancer monoclonal antibody partnering contract documents
Top cancer monoclonal antibody deals by value

The Cancer Monoclonal Antibody Partnering Agreements report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an understanding and analysis of how and why companies enter cancer monoclonal antibody partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors monoclonal antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes antibody-drug conjugate deals and alliances.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 350 links to online copies of actual cancer monoclonal antibody deals and where available, contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of cancer monoclonal antibody dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in cancer monoclonal antibody dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading cancer monoclonal antibody deals since 2009. Deals are listed by headline value, signed by big pharma, big biotech and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract
.
Chapter 4 provides a comprehensive listing of the top 50 big pharma companies with deal announcement in cancer monoclonal antibody partnering, along with a brief summary followed by a comprehensive listing of cancer monoclonal antibody deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive listing of the top 50 big biotech companies with deal announcement in cancer monoclonal antibody partnering, along with a brief summary followed by a comprehensive listing of cancer monoclonal antibody deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of cancer monoclonal antibody partnering deals signed and announced since January 2009. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy focus, and monoclonal antibody technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in cancer monoclonal antibody partnering and dealmaking since 2009.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of cancer monoclonal antibody technologies and products.


Report scope

Cancer Monoclonal Antibody Partnering Agreements is intended to provide the reader with an in-depth understanding and access to cancer monoclonal antibody trends and structure of deals entered into by leading companies worldwide.


Cancer Monoclonal Antibody Partnering Agreements includes:

Trends in cancer monoclonal antibody dealmaking in the biopharma industry since 2009
Analysis of cancer monoclonal antibody deal structure
Access to headline, upfront, milestone and royalty data
Access to over 300 cancer monoclonal antibody deal records
The leading cancer monoclonal antibody deals by value since 2009


In Cancer Monoclonal Antibody Partnering Agreements, the available deals are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific oncology therapy target
Monoclonal antibody type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Cancer Monoclonal Antibody Partnering Agreements report provides comprehensive access to available deals and contract documents for over 300 cancer monoclonal antibody deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How aresales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Executive Summary


Chapter 1 – Introduction

Chapter 2 – Trends in cancer monoclonal antibody dealmaking

2.1. Introduction
2.2. Cancer monoclonal antibody partnering over the years
2.3. Big pharma cancer monoclonal antibody dealmaking activity
2.4. Big biotech cancer monoclonal antibody dealmaking activity
2.5. Most active in cancer monoclonal antibody partnering
2.6. Cancer monoclonal antibody partnering by deal type
2.7. Cancer monoclonal antibody partnering by stage of development
2.8. Cancer monoclonal antibody partnering by cancer indication
2.9. Cancer monoclonal antibody partnering by antibody type
2.10. Disclosed deal terms for cancer monoclonal antibody partnering
2.10.1 Cancer monoclonal antibody partnering headline values
2.10.2 Cancer monoclonal antibody deal upfront payments
2.10.3 Cancer monoclonal antibody deal milestone payments
2.10.4 Cancer monoclonal antibody royalty rates

Chapter 3 – Leading cancer monoclonal antibody deals

3.1. Introduction
3.2. Top cancer monoclonal antibody deals by value

Chapter 4 – Big pharma cancer monoclonal antibody deals

4.1. Introduction

4.2. How to use big pharma partnering deals

4.3. Big pharma cancer monoclonal antibody partnering company profiles

Abbott
Abbvie
Actavis (formerly called Watson)
Amgen
Astellas
AstraZeneca
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
Chugai Pharmaceutical
CSL
Daiichi Sankyo
Eli Lilly
Fresenius
Gilead Sciences
GlaxoSmithKline
Johnson & Johnson
Merck & Co
Merck KGaA
Mitsubishi Tanabe
Novartis
Novo Nordisk
Otsuka
Pfizer
Roche
Sanofi
Servier
Takeda
Teva
UCB
Chapter 5 – Big biotech cancer monoclonal antibody deals

5.1. Introduction

5.2. How to use big biotech partnering deals

5.3. Big biotech cancer monoclonal antibody partnering company profiles

Emergent BioSolutions
Genmab
LFB Group
Morphosys
PDL BioPharma
Seattle Genetics
Spectrum Pharmaceuticals
Swedish Orphan Biovitrum

Chapter 6 – Cancer monoclonal antibody dealmaking directory

6.1. Introduction

6.2. Company A-Z

6.3. By stage of development

Discovery
Formulation
Marketed
Phase I
Phase II
Phase III
Preclinical
Regulatory

6.4. By deal type

Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Loan
Manufacturing
Marketing
Material transfer
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination

6.5. By oncology therapy area

Oncology
Bone cancer
Brain cancer
Breast cancer
Colorectal cancer
Gastric cancer
Head and neck cancer
Kidney cancer
Leukemia
Acute lymphoblastic leukemia
Acute myelogenous leukemia
Chronic lymphocytic leukemia
Lung cancer
Non small cell lung cancer
Lymphoma
Hodgkin's lymphoma
Non Hodgkin's lymphoma
Melanoma
Metastases
Multiple myeloma
Neuroblastoma
Ovarian cancer
Pancreatic cancer
Prostate cancer
Renal cell carcinoma
Solid tumors
Cancer pain
Thyroid cancer
6.6. By monoclonal antibody type
Chapter 7 –Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking
Appendices
Appendix 1 – Deal type definitions
Appendix 2 – Example monoclonal antibody cancer partnering agreement
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering
Order Form – Upgrades for subscription access products
Order Form – Therapy Reports
Order Form – Technology Reports

Table of figures

Figure 1: Cancer monoclonal antibody partnering since 2009
Figure 2: Big pharma – top 50 – cancer monoclonal antibody deals 2009 to 2014
Figure 3: Big pharma cancer monoclonal antibody deal frequency – 2009 to 2014
Figure 4: Big biotech – top 50 – cancer monoclonal antibody deals 2009 to 2014
Figure 5: Big biotech cancer monoclonal antibody deal frequency – 2009 to 2014
Figure 6: Active cancer monoclonal antibody dealmaking activity– 2009 to 2014
Figure 7: Cancer monoclonal antibody partnering by deal type since 2009
Figure 8: Cancer monoclonal antibody partnering by stage of development since 2009
Figure 9: Monoclonal antibody partnering by oncology target since 2009
Figure 10: Monoclonal antibody partnering by type since 2009
Figure 11: Cancer monoclonal antibody deals with a headline value – by stage of development
Figure 12: Cancer monoclonal antibody deal headline value distribution, US$million – discovery stage
Figure 13: Cancer monoclonal antibody deal headline value distribution, US$million – preclinical stage
Figure 14: Cancer monoclonal antibody deal headline value distribution, US$million – phase I stage
Figure 15: Cancer monoclonal antibody deal headline value distribution, US$million – phase II stage
Figure 16: Cancer monoclonal antibody deal headline value distribution, US$million – phase III stage
Figure 17: Cancer monoclonal antibody deal headline value distribution, US$million – regulatory stage
Figure 18: Cancer monoclonal antibody deal headline value distribution, US$million – marketed stage
Figure 19: Cancer monoclonal antibody deal headline value – median value by stage of development
Figure 20: Cancer monoclonal antibody deals with upfront payment values – by stage of development
Figure 21: Cancer monoclonal antibody deal upfront distribution, US$million – discovery stage
Figure 22: Cancer monoclonal antibody deal upfront value distribution, US$million – preclinical stage
Figure 23: Cancer monoclonal antibody deal upfront value distribution, US$million – phase I stage
Figure 24: Cancer monoclonal antibody deal upfront value distribution, US$million – phase II stage
Figure 25: Cancer monoclonal antibody deal upfront value distribution, US$million – phase III stage
Figure 26: Cancer monoclonal antibody deal upfront value distribution, US$million – regulatory stage
Figure 27: Cancer monoclonal antibody deal upfront value distribution, US$million – marketed stage
Figure 28: Cancer monoclonal antibody deal upfront value – median value by stage of development
Figure 29: Cancer monoclonal antibody deals with milestone payment – by stage of development
Figure 30: Cancer monoclonal antibody deal milestone distribution, US$million – discovery stage
Figure 31: Cancer monoclonal antibody deal milestone value distribution, US$million – preclinical stage
Figure 32: Cancer monoclonal antibody deal milestone value distribution, US$million – phase I stage
Figure 33: Cancer monoclonal antibody deal milestone value distribution, US$million – phase II stage
Figure 34: Cancer monoclonal antibody deal milestone value distribution, US$million – phase III stage
Figure 35: Cancer monoclonal antibody deal milestone value distribution, US$million – regulatory stage
Figure 36: Cancer monoclonal antibody deal milestone value distribution, US$million – marketed stage
Figure 37: Cancer monoclonal antibody deals with royalty rates
Figure 38: Cancer monoclonal antibody deal royalty rate distribution, US$million – discovery stage
Figure 39: Cancer monoclonal antibody deal royalty rate value distribution, US$million – preclinical stage
Figure 40: Cancer monoclonal antibody deal royalty rate value distribution, US$million – phase I stage
Figure 41: Cancer monoclonal antibody deal royalty rate value distribution, US$million – phase II stage
Figure 42: Cancer monoclonal antibody deal royalty rate value distribution, US$million – phase III stage
Figure 43: Cancer monoclonal antibody deal royalty rate value distribution, US$million – regulatory stage
Figure 44: Cance monoclonal antibody deal royalty rate value distribution, US$million – marketed stage
Figure 45: Cancer monoclonal antibody deal royalty value – median value by stage of development
Figure 46: Top cancer monoclonal antibody deals by value since 2009
Figure 47: Online partnering resources
Figure 48: Forthcoming partnering events
Figure 49: Deal type definitions
Figure 50: Collaborative R&D agreement for BiTE antibodies against three undisclosed solid tumor targets



Read the full report:
Cancer Monoclonal Antibody Partnering Terms and Agreements

https://www.reportbuyer.com/product/1112622/Cancer-Monoclonal-Antibody-Partnering-Terms-and-Agreements.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

@ThingsExpo Stories
Cultural, regulatory, environmental, political and economic (CREPE) conditions over the past decade are creating cross-industry solution spaces that require processes and technologies from both the Internet of Things (IoT), and Data Management and Analytics (DMA). These solution spaces are evolving into Sensor Analytics Ecosystems (SAE) that represent significant new opportunities for organizations of all types. Public Utilities throughout the world, providing electricity, natural gas and water, are pursuing SmartGrid initiatives that represent one of the more mature examples of SAE. We have s...
The Internet of Things (IoT) is going to require a new way of thinking and of developing software for speed, security and innovation. This requires IT leaders to balance business as usual while anticipating for the next market and technology trends. Cloud provides the right IT asset portfolio to help today’s IT leaders manage the old and prepare for the new. Today the cloud conversation is evolving from private and public to hybrid. This session will provide use cases and insights to reinforce the value of the network in helping organizations to maximize their company’s cloud experience.
IoT is still a vague buzzword for many people. In his session at Internet of @ThingsExpo, Mike Kavis, Vice President & Principal Cloud Architect at Cloud Technology Partners, will discuss the business value of IoT that goes far beyond the general public's perception that IoT is all about wearables and home consumer services. The presentation will also discuss how IoT is perceived by investors and how venture capitalist access this space. Other topics to discuss are barriers to success, what is new, what is old, and what the future may hold.
Whether you're a startup or a 100 year old enterprise, the Internet of Things offers a variety of new capabilities for your business. IoT style solutions can help you get closer your customers, launch new product lines and take over an industry. Some companies are dipping their toes in, but many have already taken the plunge, all while dramatic new capabilities continue to emerge. In his session at Internet of @ThingsExpo, Reid Carlberg, Senior Director, Developer Evangelism at salesforce.com, to discuss real-world use cases, patterns and opportunities you can harness today.
All major researchers estimate there will be tens of billions devices – computers, smartphones, tablets, and sensors – connected to the Internet by 2020. This number will continue to grow at a rapid pace for the next several decades. With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo in Silicon Valley. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as "IoT-Ready" as it can be!
Noted IoT expert and researcher Joseph di Paolantonio (pictured below) has joined the @ThingsExpo faculty. Joseph, who describes himself as an “Independent Thinker” from DataArchon, will speak on the topic of “Smart Grids & Managing Big Utilities.” Over his career, Joseph di Paolantonio has worked in the energy, renewables, aerospace, telecommunications, and information technology industries. His expertise is in data analysis, system engineering, Bayesian statistics, data warehouses, business intelligence, data mining, predictive methods, and very large databases (VLDB). Prior to DataArcho...
Software AG helps organizations transform into Digital Enterprises, so they can differentiate from competitors and better engage customers, partners and employees. Using the Software AG Suite, companies can close the gap between business and IT to create digital systems of differentiation that drive front-line agility. We offer four on-ramps to the Digital Enterprise: alignment through collaborative process analysis; transformation through portfolio management; agility through process automation and integration; and visibility through intelligent business operations and big data.
There will be 50 billion Internet connected devices by 2020. Today, every manufacturer has a propriety protocol and an app. How do we securely integrate these "things" into our lives and businesses in a way that we can easily control and manage? Even better, how do we integrate these "things" so that they control and manage each other so our lives become more convenient or our businesses become more profitable and/or safe? We have heard that the best interface is no interface. In his session at Internet of @ThingsExpo, Chris Matthieu, Co-Founder & CTO at Octoblu, Inc., will discuss how thes...
Last week, while in San Francisco, I used the Uber app and service four times. All four experiences were great, although one of the drivers stopped for 30 seconds and then left as I was walking up to the car. He must have realized I was a blogger. None the less, the next car was just a minute away and I suffered no pain. In this article, my colleague, Ved Sen, Global Head, Advisory Services Social, Mobile and Sensors at Cognizant shares his experiences and insights.
We are reaching the end of the beginning with WebRTC and real systems using this technology have begun to appear. One challenge that faces every WebRTC deployment (in some form or another) is identity management. For example, if you have an existing service – possibly built on a variety of different PaaS/SaaS offerings – and you want to add real-time communications you are faced with a challenge relating to user management, authentication, authorization, and validation. Service providers will want to use their existing identities, but these will have credentials already that are (hopefully) ir...
Can call centers hang up the phones for good? Intuitive Solutions did. WebRTC enabled this contact center provider to eliminate antiquated telephony and desktop phone infrastructure with a pure web-based solution, allowing them to expand beyond brick-and-mortar confines to a home-based agent model. It also ensured scalability and better service for customers, including MUY! Companies, one of the country's largest franchise restaurant companies with 232 Pizza Hut locations. This is one example of WebRTC adoption today, but the potential is limitless when powered by IoT. Attendees will learn rea...
From telemedicine to smart cars, digital homes and industrial monitoring, the explosive growth of IoT has created exciting new business opportunities for real time calls and messaging. In his session at Internet of @ThingsExpo, Ivelin Ivanov, CEO and Co-Founder of Telestax, will share some of the new revenue sources that IoT created for Restcomm – the open source telephony platform from Telestax. Ivelin Ivanov is a technology entrepreneur who founded Mobicents, an Open Source VoIP Platform, to help create, deploy, and manage applications integrating voice, video and data. He is the co-founder ...
The Internet of Things (IoT) promises to create new business models as significant as those that were inspired by the Internet and the smartphone 20 and 10 years ago. What business, social and practical implications will this phenomenon bring? That's the subject of "Monetizing the Internet of Things: Perspectives from the Front Lines," an e-book released today and available free of charge from Aria Systems, the leading innovator in recurring revenue management.
The Internet of Things will put IT to its ultimate test by creating infinite new opportunities to digitize products and services, generate and analyze new data to improve customer satisfaction, and discover new ways to gain a competitive advantage across nearly every industry. In order to help corporate business units to capitalize on the rapidly evolving IoT opportunities, IT must stand up to a new set of challenges.
There’s Big Data, then there’s really Big Data from the Internet of Things. IoT is evolving to include many data possibilities like new types of event, log and network data. The volumes are enormous, generating tens of billions of logs per day, which raise data challenges. Early IoT deployments are relying heavily on both the cloud and managed service providers to navigate these challenges. In her session at 6th Big Data Expo®, Hannah Smalltree, Director at Treasure Data, to discuss how IoT, Big Data and deployments are processing massive data volumes from wearables, utilities and other mach...
P2P RTC will impact the landscape of communications, shifting from traditional telephony style communications models to OTT (Over-The-Top) cloud assisted & PaaS (Platform as a Service) communication services. The P2P shift will impact many areas of our lives, from mobile communication, human interactive web services, RTC and telephony infrastructure, user federation, security and privacy implications, business costs, and scalability. In his session at Internet of @ThingsExpo, Erik Lagerway, Co-founder of Hookflash, will walk through the shifting landscape of traditional telephone and voice s...
While great strides have been made relative to the video aspects of remote collaboration, audio technology has basically stagnated. Typically all audio is mixed to a single monaural stream and emanates from a single point, such as a speakerphone or a speaker associated with a video monitor. This leads to confusion and lack of understanding among participants especially regarding who is actually speaking. Spatial teleconferencing introduces the concept of acoustic spatial separation between conference participants in three dimensional space. This has been shown to significantly improve comprehe...
The Internet of Things is tied together with a thin strand that is known as time. Coincidentally, at the core of nearly all data analytics is a timestamp. When working with time series data there are a few core principles that everyone should consider, especially across datasets where time is the common boundary. In his session at Internet of @ThingsExpo, Jim Scott, Director of Enterprise Strategy & Architecture at MapR Technologies, will discuss single-value, geo-spatial, and log time series data. By focusing on enterprise applications and the data center, he will use OpenTSDB as an example...
SYS-CON Events announced today that Gridstore™, the leader in software-defined storage (SDS) purpose-built for Windows Servers and Hyper-V, will exhibit at SYS-CON's 15th International Cloud Expo®, which will take place on November 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA. Gridstore™ is the leader in software-defined storage purpose built for virtualization that is designed to accelerate applications in virtualized environments. Using its patented Server-Side Virtual Controller™ Technology (SVCT) to eliminate the I/O blender effect and accelerate applications Gridsto...
The Transparent Cloud-computing Consortium (abbreviation: T-Cloud Consortium) will conduct research activities into changes in the computing model as a result of collaboration between "device" and "cloud" and the creation of new value and markets through organic data processing High speed and high quality networks, and dramatic improvements in computer processing capabilities, have greatly changed the nature of applications and made the storing and processing of data on the network commonplace. These technological reforms have not only changed computers and smartphones, but are also changi...